enVVeno Medical Statistics
Total Valuation
enVVeno Medical has a market cap or net worth of $6.44 million. The enterprise value is -$17.90 million.
Important Dates
The last earnings date was Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
enVVeno Medical has 655,521 shares outstanding. The number of shares has increased by 16.65% in one year.
| Current Share Class | 655,521 |
| Shares Outstanding | 655,521 |
| Shares Change (YoY) | +16.65% |
| Shares Change (QoQ) | +5.96% |
| Owned by Insiders (%) | 9.07% |
| Owned by Institutions (%) | 10.48% |
| Float | 524,178 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 0.68 |
| PB Ratio | 0.27 |
| P/TBV Ratio | 0.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.89, with a Debt / Equity ratio of 0.03.
| Current Ratio | 11.89 |
| Quick Ratio | 11.63 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -60.65% and return on invested capital (ROIC) is -39.30%.
| Return on Equity (ROE) | -60.65% |
| Return on Assets (ROA) | -37.51% |
| Return on Invested Capital (ROIC) | -39.30% |
| Return on Capital Employed (ROCE) | -83.52% |
| Weighted Average Cost of Capital (WACC) | 9.34% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$570,242 |
| Employee Count | 33 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.22% in the last 52 weeks. The beta is 1.08, so enVVeno Medical's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | -92.22% |
| 50-Day Moving Average | 10.98 |
| 200-Day Moving Average | 27.32 |
| Relative Strength Index (RSI) | 42.18 |
| Average Volume (20 Days) | 13,743 |
Short Selling Information
The latest short interest is 60,362, so 9.21% of the outstanding shares have been sold short.
| Short Interest | 60,362 |
| Short Previous Month | 76,169 |
| Short % of Shares Out | 9.21% |
| Short % of Float | 11.52% |
| Short Ratio (days to cover) | 7.76 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -20.01M |
| Pretax Income | -18.82M |
| Net Income | -18.82M |
| EBITDA | -19.88M |
| EBIT | -20.01M |
| Earnings Per Share (EPS) | -$30.99 |
Full Income StatementBalance Sheet
The company has $24.93 million in cash and $603,000 in debt, with a net cash position of $24.33 million or $37.11 per share.
| Cash & Cash Equivalents | 24.93M |
| Total Debt | 603,000 |
| Net Cash | 24.33M |
| Net Cash Per Share | $37.11 |
| Equity (Book Value) | 23.75M |
| Book Value Per Share | 36.20 |
| Working Capital | 23.35M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.79 million and capital expenditures -$5,000, giving a free cash flow of -$14.79 million.
| Operating Cash Flow | -14.79M |
| Capital Expenditures | -5,000 |
| Depreciation & Amortization | 127,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -14.79M |
| FCF Per Share | -$22.57 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
enVVeno Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.65% |
| Shareholder Yield | -16.65% |
| Earnings Yield | -292.63% |
| FCF Yield | -230.04% |
Analyst Forecast
The average price target for enVVeno Medical is $437.50, which is 4,350.66% higher than the current price. The consensus rating is "Hold".
| Price Target | $437.50 |
| Price Target Difference | 4,350.66% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 20, 2026. It was a reverse split with a ratio of 1:35.
| Last Split Date | Jan 20, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:35 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
